Ciltacabtagene autoleucel, an investigational BCMA-directed CAR-T therapy, sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Recent Content
- Scientists find new way to kill treatment-resistant myeloma cells
- Phase 3 blood cancer vaccine trial moves toward final analysis
- Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review
- MajesTEC results with teclistamab in relapsed and/or refractory multiple myeloma
- Phase 3 trial testing if oral pill can stop pancreatic cancer from returning
- (no title)
- Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma
- CAR T-cells in multiple myeloma: the race to the start line
- Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia
- Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO